Literature DB >> 33766067

LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study.

Yang Zou1, Ling Zhong2, Chong Hu3, Mingchun Zhong1, Nan Peng1, Guotai Sheng4.   

Abstract

BACKGROUND: Low-density lipoprotein to high density lipoprotein (LDL/HDL) cholesterol ratio has been reported to predict the risk of many metabolic diseases. However, the association between the LDL/HDL cholesterol ratio and nonalcoholic fatty liver disease (NAFLD) has not been established.
METHODS: A longitudinal cohort design was adopted in this study; 9767 non-obese subjects without NAFLD were included and analyzed. The subjects were grouped according to the quintile of LDL/HDL cholesterol ratio. The cumulative incidence of NAFLD and the independent effect of the LDL/HDL cholesterol ratio on NAFLD during 5 years of follow-up were calculated using the Kaplan-Meier method and Cox proportional-hazards regression model.
RESULTS: During the 5-year follow-up period, 841 subjects were diagnosed with new-onset NAFLD, and the 1-, 2-, 3-, 4-, and 5-year cumulative incidence rates of NAFLD were 1.16, 4.65, 8.33, 12.43, and 25.14%, respectively. In the multivariable-adjusted Cox proportional-hazards regression model, the LDL/HDL cholesterol ratio was significantly associated with the risk for NAFLD (HR: 1.66, 95% CI: 1.38-1.99, P trend< 0.001), especially among young people (HR: 3.96, 95% CI: 1.50-10.46, P interaction< 0.05). Additionally, receiver operating characteristic curve analysis showed that the LDL/HDL cholesterol ratio was better than HDL cholesterol and LDL cholesterol in predicting new-onset NAFLD.
CONCLUSIONS: LDL/HDL cholesterol ratio is an independent predictor of NAFLD in Chinese non-obese people with normal lipids, and its predictive value is higher than that of other lipoproteins. In clinical practice, the LDL/HDL cholesterol ratio can be used to identify people at high risk of NAFLD.

Entities:  

Keywords:  LDL/HDL cholesterol ratio; Lipoprotein ratios; Longitudinal study; Non-obese; Nonalcoholic fatty liver disease

Year:  2021        PMID: 33766067     DOI: 10.1186/s12944-021-01457-1

Source DB:  PubMed          Journal:  Lipids Health Dis        ISSN: 1476-511X            Impact factor:   3.876


  37 in total

Review 1.  Nonalcoholic Fatty Liver Disease.

Authors:  Xiao Jing Wang; Harmeet Malhi
Journal:  Ann Intern Med       Date:  2018-11-06       Impact factor: 25.391

Review 2.  Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.

Authors:  Stergios A Polyzos; Jannis Kountouras; Christos S Mantzoros
Journal:  Metabolism       Date:  2018-11-29       Impact factor: 8.694

Review 3.  Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future.

Authors:  Ana Ruth Araújo; Natalia Rosso; Giorgio Bedogni; Claudio Tiribelli; Stefano Bellentani
Journal:  Liver Int       Date:  2018-02       Impact factor: 5.828

4.  Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.

Authors:  Jingjing Cai; Xiao-Jing Zhang; Yan-Xiao Ji; Peng Zhang; Zhi-Gang She; Hongliang Li
Journal:  Circ Res       Date:  2020-02-27       Impact factor: 17.367

Review 5.  Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.

Authors:  Vignan Manne; Priya Handa; Kris V Kowdley
Journal:  Clin Liver Dis       Date:  2017-10-18       Impact factor: 6.126

Review 6.  Lean non-alcoholic fatty liver disease.

Authors:  Alice Yuxin Wang; Jasbir Dhaliwal; Marialena Mouzaki
Journal:  Clin Nutr       Date:  2018-08-17       Impact factor: 7.324

Review 7.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

8.  Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Qing Ye; Biyao Zou; Yee Hui Yeo; Jie Li; Daniel Q Huang; Yuankai Wu; Hongli Yang; Chuanli Liu; Leslie Y Kam; Xiang Xuan Eunice Tan; Nicholas Chien; Sam Trinh; Linda Henry; Christopher Donald Stave; Tetsuya Hosaka; Ramsey C Cheung; Mindie H Nguyen
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05-12

Review 9.  Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease.

Authors:  Maria Catalina Hernandez-Rodas; Rodrigo Valenzuela; Luis A Videla
Journal:  Int J Mol Sci       Date:  2015-10-23       Impact factor: 5.923

Review 10.  Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.

Authors:  Brandon J Perumpail; Muhammad Ali Khan; Eric R Yoo; George Cholankeril; Donghee Kim; Aijaz Ahmed
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

View more
  12 in total

1.  Total cholesterol to high-density lipoprotein ratio and nonalcoholic fatty liver disease in a population with chronic hepatitis B.

Authors:  Yu-Ge Zhou; Ning Tian; Wei-Ning Xie
Journal:  World J Hepatol       Date:  2022-04-27

2.  Association of LDL:HDL ratio with prediabetes risk: a longitudinal observational study based on Chinese adults.

Authors:  Maobin Kuang; Nan Peng; Jiajun Qiu; Yanjia Zhong; Yang Zou; Guotai Sheng
Journal:  Lipids Health Dis       Date:  2022-05-15       Impact factor: 4.315

3.  Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population.

Authors:  Jiawang Zou; Hailan Xiong; Huimin Zhang; Chong Hu; Song Lu; Yang Zou
Journal:  BMC Gastroenterol       Date:  2022-01-12       Impact factor: 3.067

4.  Dose-Response Associations of Metabolic Score for Insulin Resistance Index with Nonalcoholic Fatty Liver Disease among a Nonobese Chinese Population: Retrospective Evidence from a Population-Based Cohort Study.

Authors:  Xintian Cai; Jing Gao; Junli Hu; Wen Wen; Qing Zhu; Mengru Wang; Shasha Liu; Jing Hong; Ting Wu; Shunfan Yang; Guzailinuer Tuerxun; Nanfang Li
Journal:  Dis Markers       Date:  2022-02-23       Impact factor: 3.434

5.  Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China.

Authors:  Jingrui Wang; Zhenzhen Su; Yijin Feng; Ruihan Xi; Jiamin Liu; Peixi Wang
Journal:  BMC Gastroenterol       Date:  2021-12-19       Impact factor: 3.067

6.  Higher serum uric acid to HDL-cholesterol ratio is associated with onset of non-alcoholic fatty liver disease in a non-obese Chinese population with normal blood lipid levels.

Authors:  Wentao Zhu; An Liang; Pei Shi; Songsong Yuan; Ying Zhu; Jiwei Fu; Ting Zheng; Zhilong Wen; Xiaoping Wu
Journal:  BMC Gastroenterol       Date:  2022-04-21       Impact factor: 2.847

7.  Dyslipidemia and 10-year diabetes incidence in Japanese people: Population-based Panasonic cohort study 9.

Authors:  Genki Kobayashi; Hiroshi Okada; Masahide Hamaguchi; Kazushiro Kurogi; Hiroaki Murata; Masato Ito; Michiaki Fukui
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

8.  Association of mean arterial pressure with 5-year risk of incident diabetes in Chinese adults:a secondary population-based cohort study.

Authors:  Yang Wu; Haofei Hu; Jinlin Cai; Runtian Chen; Xin Zuo; Heng Cheng; Dewen Yan
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

9.  Remnant cholesterol/high-density lipoprotein cholesterol ratio is a new powerful tool for identifying non-alcoholic fatty liver disease.

Authors:  Yang Zou; Chong Hu; Maobin Kuang; Yuliang Chai
Journal:  BMC Gastroenterol       Date:  2022-03-24       Impact factor: 3.067

10.  Usefulness of the triglyceride glucose-body mass index in evaluating nonalcoholic fatty liver disease: insights from a general population.

Authors:  Rongsheng Wang; Longlong Dai; Yanjia Zhong; Guobo Xie
Journal:  Lipids Health Dis       Date:  2021-07-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.